Designed to assess the safety, tolerability and efficacy of CCX140, the randomised, double-blind, placebo-controlled study is being conducted at 90 sites throughout Europe.
ChemoCentryx president and chief executive officer Thomas Schall said with an over-enrolment of patients in the study, the company completed the important Phase II enrolment milestone.
"This achievement will enable us to report 12-week data in approximately 200 patients in the third quarter of 2013, on track with our timeline projections," Schall added.
The study subjects will be randomized with either oral CCX140 at a dose of either 5mg or 10mg, or a placebo one time each day.
Initially, the efficacy of the drug on protein levels, or proteinuria, and haemoglobin A1c will be evaluated in the 12-week interim analysis.
In a subsequent 52-week analysis, the potential benefits of CCX140 on kidney function such as effects on serum creatinine and estimated glomerular filtration rate levels, among other measures of kidney health, will be assessed.
The company expects study data in the third quarter of 2014.